Substitute offered for Cox III inhibitors

The German biotech-company, Orthogen AG, has provided an substitute by offering the results of a new osteoarthritis trial with Orthokine.

It was remarked by Orthogen CEO Prof. MD. Peter Wehling in Dusseldorf/North-Rhine-Westfalia, that the Orthokine-therapy is safe as well as effective. It was also remarked that clinical results have suggested that the therapy results are far superior to those achieved using standard hyaluronic acid injection therapy and placebo.

From News-Medical.Net:

Ten to 20 percent of the population of western countries suffers from joint and spinal disorders. The therapies for these disorders are most expensive after circulatory and digestive diseases with a high market potential. According to official government statistics, orthopedic disorders cost EUR25 billion annually in Germany alone and approximately one-third of this amount is accounted by osteoarthritis. For many years now, musculoskeletal disorders have been the number one cause of work disability and the consequent economic loss in Germany.

“The problem with conventional OA-therapies such as painkillers, steroids and hyaluronic acid is that they act on the symptoms but leave the underlying causes of the disease untouched,” said Wehling, specialized in the role of cytokines in pain inhibition and tissue regeneration. In contrast Orthokine acts on the causal mechanism of arthritis and prevents further cartilage degeneration in the joints. “Orthokine could potentially become the new standard arthritis therapy,” Wehling said. Pharmacology experts also regard biologicals as the medications of the future.

The trial included 400 Patients and was realized in conformity with the international standards from Heinrich-Heine-University (Dusseldorf).

Tags: arthritis, Orthokine, osteoarthritis, placebo, Steroids

You can leave a response, or trackback from your own site.